BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 23092569)

  • 1. [ALK gene mutations in childhood neuroblastoma].
    Yang CL; Yue LJ; Jiang XP; Wen FQ; Zheng MM
    Zhongguo Dang Dai Er Ke Za Zhi; 2012 Oct; 14(10):763-6. PubMed ID: 23092569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Abnormality of anaplastic lymphoma kinase gene and its expression in pediatric neuroblastoma].
    Chen S; Zhou C; Ma X; Gong L
    Zhonghua Bing Li Xue Za Zhi; 2014 Aug; 43(8):541-5. PubMed ID: 25346125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of tumor ALK status in neuroblastoma patients using peripheral blood.
    Combaret V; Iacono I; Bellini A; Bréjon S; Bernard V; Marabelle A; Coze C; Pierron G; Lapouble E; Schleiermacher G; Blay JY
    Cancer Med; 2015 Apr; 4(4):540-50. PubMed ID: 25653133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Copy number status and mutation analyses of anaplastic lymphoma kinase (ALK) gene in 90 sporadic neuroblastoma tumors.
    Bagci O; Tumer S; Olgun N; Altungoz O
    Cancer Lett; 2012 Apr; 317(1):72-7. PubMed ID: 22085494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncogenic anaplastic lymphoma kinase (ALK) mutation in neuroblastomas and other pediatric tumors.
    Kwon MJ; Choi YL; Sung KW; Kang SY; Park SM; Choi SY; Kim JS; Suh YL
    Pathol Res Pract; 2011 Oct; 207(10):634-9. PubMed ID: 21940108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deep Sequencing Reveals Occurrence of Subclonal ALK Mutations in Neuroblastoma at Diagnosis.
    Bellini A; Bernard V; Leroy Q; Rio Frio T; Pierron G; Combaret V; Lapouble E; Clement N; Rubie H; Thebaud E; Chastagner P; Defachelles AS; Bergeron C; Buchbinder N; Taque S; Auvrignon A; Valteau-Couanet D; Michon J; Janoueix-Lerosey I; Delattre O; Schleiermacher G
    Clin Cancer Res; 2015 Nov; 21(21):4913-21. PubMed ID: 26059187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical feature of anaplastic lymphoma kinase-mutated neuroblastoma.
    Ogura T; Hiyama E; Kamei N; Kamimatsuse A; Ueda Y; Ogura K
    J Pediatr Surg; 2012 Oct; 47(10):1789-96. PubMed ID: 23084186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours.
    Carén H; Abel F; Kogner P; Martinsson T
    Biochem J; 2008 Dec; 416(2):153-9. PubMed ID: 18990089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intragenic anaplastic lymphoma kinase (ALK) rearrangements: translocations as a novel mechanism of ALK activation in neuroblastoma tumors.
    Fransson S; Hansson M; Ruuth K; Djos A; Berbegall A; Javanmardi N; Abrahamsson J; Palmer RH; Noguera R; Hallberg B; Kogner P; Martinsson T
    Genes Chromosomes Cancer; 2015 Feb; 54(2):99-109. PubMed ID: 25251827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma.
    Schulte JH; Bachmann HS; Brockmeyer B; Depreter K; Oberthür A; Ackermann S; Kahlert Y; Pajtler K; Theissen J; Westermann F; Vandesompele J; Speleman F; Berthold F; Eggert A; Brors B; Hero B; Schramm A; Fischer M
    Clin Cancer Res; 2011 Aug; 17(15):5082-92. PubMed ID: 21632861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genome-wide linkage analysis to identify genetic modifiers of ALK mutation penetrance in familial neuroblastoma.
    Devoto M; Specchia C; Laudenslager M; Longo L; Hakonarson H; Maris J; Mossé Y
    Hum Hered; 2011; 71(2):135-9. PubMed ID: 21734404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ALK Protein Expression Is Related to Neuroblastoma Aggressiveness But Is Not Independent Prognostic Factor.
    Lee JW; Park SH; Kang HJ; Park KD; Shin HY; Ahn HS
    Cancer Res Treat; 2018 Apr; 50(2):495-505. PubMed ID: 28546523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK.
    Di Paolo D; Yang D; Pastorino F; Emionite L; Cilli M; Daga A; Destafanis E; Di Fiore A; Piaggio F; Brignole C; Xu X; Liang C; Gibbons J; Ponzoni M; Perri P
    Oncotarget; 2015 Oct; 6(30):28774-89. PubMed ID: 26299615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platform comparison for evaluation of ALK protein immunohistochemical expression, genomic copy number and hotspot mutation status in neuroblastomas.
    Yan B; Kuick CH; Lim M; Venkataraman K; Tennakoon C; Loh E; Lian D; Leong MY; Lakshmanan M; Tergaonkar V; Sung WK; Soh SY; Chang KT
    PLoS One; 2014; 9(9):e106575. PubMed ID: 25188507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emergence of new ALK mutations at relapse of neuroblastoma.
    Schleiermacher G; Javanmardi N; Bernard V; Leroy Q; Cappo J; Rio Frio T; Pierron G; Lapouble E; Combaret V; Speleman F; de Wilde B; Djos A; Ora I; Hedborg F; Träger C; Holmqvist BM; Abrahamsson J; Peuchmaur M; Michon J; Janoueix-Lerosey I; Kogner P; Delattre O; Martinsson T
    J Clin Oncol; 2014 Sep; 32(25):2727-34. PubMed ID: 25071110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germline gain-of-function mutations of ALK disrupt central nervous system development.
    de Pontual L; Kettaneh D; Gordon CT; Oufadem M; Boddaert N; Lees M; Balu L; Lachassinne E; Petros A; Mollet J; Wilson LC; Munnich A; Brugière L; Delattre O; Vekemans M; Etchevers H; Lyonnet S; Janoueix-Lerosey I; Amiel J
    Hum Mutat; 2011 Mar; 32(3):272-6. PubMed ID: 21972109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutation-Independent Activation of the Anaplastic Lymphoma Kinase in Neuroblastoma.
    Regairaz M; Munier F; Sartelet H; Castaing M; Marty V; Renauleaud C; Doux C; Delbé J; Courty J; Fabre M; Ohta S; Vielh P; Michiels S; Valteau-Couanet D; Vassal G
    Am J Pathol; 2016 Feb; 186(2):435-45. PubMed ID: 26687816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome.
    Padovan-Merhar OM; Raman P; Ostrovnaya I; Kalletla K; Rubnitz KR; Sanford EM; Ali SM; Miller VA; Mossé YP; Granger MP; Weiss B; Maris JM; Modak S
    PLoS Genet; 2016 Dec; 12(12):e1006501. PubMed ID: 27997549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low Frequency ALK Hotspots Mutations In Neuroblastoma Tumours Detected By Ultra-deep Sequencing: Implications For ALK Inhibitor Treatment.
    Javanmardi N; Fransson S; Djos A; Sjöberg RM; Nilsson S; Truvé K; Kogner P; Martinsson T
    Sci Rep; 2019 Feb; 9(1):2199. PubMed ID: 30778092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of rearrangements involving the ALK gene reveals a novel truncated form associated with tumor aggressiveness in neuroblastoma.
    Cazes A; Louis-Brennetot C; Mazot P; Dingli F; Lombard B; Boeva V; Daveau R; Cappo J; Combaret V; Schleiermacher G; Jouannet S; Ferrand S; Pierron G; Barillot E; Loew D; Vigny M; Delattre O; Janoueix-Lerosey I
    Cancer Res; 2013 Jan; 73(1):195-204. PubMed ID: 23139213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.